Acorda Therapeutics Company Profile (NASDAQ:ACOR)

About Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics logoAcorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Industry, Sector and Symbol:
  • Sector:
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ACOR
  • CUSIP: 00484M10
  • Web:
  • Market Cap: $666.3 million
  • Outstanding Shares: 46,758,000
Average Prices:
  • 50 Day Moving Avg: $15.91
  • 200 Day Moving Avg: $20.74
  • 52 Week Range: $14.15 - $33.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 13.57
  • P/E Growth: 0.25
Sales & Book Value:
  • Annual Revenue: $523.08 million
  • Price / Sales: 1.27
  • Book Value: $14.46 per share
  • Price / Book: 0.99
  • EBIDTA: $20.62 million
  • Net Margins: -4.38%
  • Return on Equity: -1.66%
  • Return on Assets: -0.88%
  • Debt-to-Equity Ratio: 0.45%
  • Current Ratio: 2.01%
  • Quick Ratio: 1.67%
  • Average Volume: 1.12 million shs.
  • Beta: 1.53
  • Short Ratio: 5.25

Frequently Asked Questions for Acorda Therapeutics (NASDAQ:ACOR)

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics Inc (NASDAQ:ACOR) posted its quarterly earnings results on Thursday, April, 27th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.08. The business earned $119.39 million during the quarter, compared to analyst estimates of $127.34 million. Acorda Therapeutics had a negative net margin of 4.38% and a negative return on equity of 1.66%. The company's quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.28 EPS. View Acorda Therapeutics' Earnings History.

When will Acorda Therapeutics make its next earnings announcement?

Acorda Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Acorda Therapeutics.

Where is Acorda Therapeutics' stock going? Where will Acorda Therapeutics' stock price be in 2017?

9 brokerages have issued 1-year target prices for Acorda Therapeutics' stock. Their predictions range from $19.00 to $52.00. On average, they expect Acorda Therapeutics' share price to reach $28.00 in the next year. View Analyst Ratings for Acorda Therapeutics.

What are analysts saying about Acorda Therapeutics stock?

Here are some recent quotes from research analysts about Acorda Therapeutics stock:

  • 1. According to Zacks Investment Research, "Acorda’s flagship product Ampyra has been doing well and is expected to continue doing so. Promotional efforts and increasing awareness should help sales growth. Meanwhile, Acorda continues to work on expanding its pipeline by entering into deals and pursuing acquisitions. The company’s share price outperformed the industry in past three months. However, with Ampyra facing several patent challenges, focus will remain on the company’s pipeline development efforts and ability to bring new products to market. Moreover, Acorda recently discontinued the development of Ampyra for post-stroke walking difficulties, which hurt investor sentiment. Estimates have remained stable lately ahead of the company’s Q4 earnings release. The company has positive record of earnings surprises in recent quarters." (1/23/2017)
  • 2. Cowen and Company analysts commented, "ACOR released Q4 Ampyra revenue and provided 2017 Ampyra guidance, both just." (1/9/2017)

Who are some of Acorda Therapeutics' key competitors?

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the folowing people:

  • Ron Cohen M.D., President,Chief Executive Officer, Director
  • David Lawrence, Chief Business Operations, Principal Accounting Officer
  • Andrew R. Blight Ph.D., Chief Scientific Officer
  • Jane Wasman J.D., President - International, General Counsel, Corporate Secretary
  • Burkhard Blank M.D., Chief Medical Officer
  • Andrew Hindman, Chief Business Development Officer
  • Lauren M. Sabella, Chief Commercial Officer
  • Catherine D. Strader, Director
  • Barry E. Greene, Independent Director
  • Peder K. Jensen M.D., Independent Director

Who owns Acorda Therapeutics stock?

Acorda Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (0.00%), SCOPIA CAPITAL MANAGEMENT LP (12.00%), Vanguard Group Inc. (0.00%), Dimensional Fund Advisors LP (0.00%), State Street Corp (3.55%) and Cambiar Investors LLC (1.82%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Andrew Blight, David Lawrence, Enrique J Carrazana, Ian F Smith, Jane Wasman, Lauren M Sabella, Lorin Randall, Michael W Rogers, Richard P Batycky, Ron Cohen and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.

Who sold Acorda Therapeutics stock? Who is selling Acorda Therapeutics stock?

Acorda Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, FMR LLC, Wellington Management Group LLP, Oxford Asset Management, Teachers Advisors LLC, Spark Investment Management LLC, Strs Ohio and Pictet Asset Management Ltd.. Company insiders that have sold Acorda Therapeutics stock in the last year include Andrew A Hindman, David Lawrence, Jane Wasman, Richard P Batycky, Ron Cohen and Steven M Rauscher. View Insider Buying and Selling for Acorda Therapeutics.

Who bought Acorda Therapeutics stock? Who is buying Acorda Therapeutics stock?

Acorda Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Cambiar Investors LLC, Loomis Sayles & Co. L P, RA Capital Management LLC, United Services Automobile Association, Dimensional Fund Advisors LP, Vanguard Group Inc., Prudential Financial Inc. and Icon Advisers Inc. Co.. View Insider Buying and Selling for Acorda Therapeutics.

How do I buy Acorda Therapeutics stock?

Shares of Acorda Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of Acorda Therapeutics stock can currently be purchased for approximately $14.25.

MarketBeat Community Rating for Acorda Therapeutics (NASDAQ ACOR)
Community Ranking:  2.2 out of 5 ( )
Outperform Votes:  174 (Vote Outperform)
Underperform Votes:  225 (Vote Underperform)
Total Votes:  399
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Acorda Therapeutics (NASDAQ:ACOR) (?)
Ratings Breakdown: 5 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $28.00 (96.49% upside)

Analysts' Ratings History for Acorda Therapeutics (NASDAQ:ACOR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/3/2017Cowen and CompanyLower Price TargetOutperform$60.00 -> $35.00HighView Rating Details
4/3/2017Goldman Sachs Group IncReiterated RatingNeutral$22.00HighView Rating Details
4/3/2017JPMorgan Chase & Co.DowngradeOverweight -> Neutral$32.00 -> $24.00HighView Rating Details
4/3/2017Janney Montgomery ScottDowngradeBuy -> Neutral$38.00 -> $19.00HighView Rating Details
3/30/2017Stifel NicolausReiterated RatingBuy$30.00HighView Rating Details
2/15/2017Cantor FitzgeraldReiterated RatingNeutral -> PositiveN/AView Rating Details
1/8/2017Evercore ISISet Price TargetHold$23.00N/AView Rating Details
11/23/2016Leerink SwannReiterated RatingMarket PerformN/AView Rating Details
6/1/2016AegisBoost Price TargetBuy$40.00 -> $52.00N/AView Rating Details
8/31/2015Raymond James Financial, Inc.Initiated CoverageMarket PerformN/AView Rating Details
7/31/2015Canaccord GenuityReiterated RatingHold$32.00N/AView Rating Details
6/22/2015MLV & Co.Set Price TargetBuy$58.00N/AView Rating Details
6/9/2015GuggenheimInitiated CoverageNeutralN/AView Rating Details
(Data available from 5/30/2015 forward)


Earnings History for Acorda Therapeutics (NASDAQ:ACOR)
Earnings by Quarter for Acorda Therapeutics (NASDAQ:ACOR)
Earnings History by Quarter for Acorda Therapeutics (NASDAQ ACOR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2017Q1 2017($0.16)($0.08)$127.34 million$119.39 millionViewN/AView Earnings Details
2/14/2017Q416($0.18)$0.05$137.90 million$140.63 millionViewListenView Earnings Details
10/27/2016Q316($0.26)($0.04)$134.01 million$135.61 millionViewListenView Earnings Details
7/28/2016Q216$0.18$0.07$128.33 million$127.45 millionViewListenView Earnings Details
4/28/2016Q116$0.08$0.07$115.36 million$115.90 millionViewListenView Earnings Details
2/11/2016Q415$0.22$0.28$128.24 million$130.90 millionViewListenView Earnings Details
10/22/2015Q315$0.15$0.31$115.52 million$148.20 millionViewListenView Earnings Details
7/30/2015Q215($0.01)$0.31$110.84 million$113.70 millionViewListenView Earnings Details
4/30/2015Q115$0.03($0.02)$100.20 million$99.85 millionViewN/AView Earnings Details
2/12/2015Q414$0.15$0.33$110.80 million$117.90 millionViewN/AView Earnings Details
10/30/2014Q314$0.04$0.34$94.70 million$106.00 millionViewN/AView Earnings Details
7/31/2014Q214$0.14$0.24$91.40 million$97.13 millionViewN/AView Earnings Details
5/6/2014Q114$0.04$0.08$81.30 million$80.52 millionViewN/AView Earnings Details
2/19/2014Q413$0.18$0.32$89.96 million$92.59 millionViewN/AView Earnings Details
10/31/2013Q313$0.13$0.36$90.01 million$84.92 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.09$0.25$82.57 million$87.05 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.20$0.09$80.77 million$71.90 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.15$0.24$78.90 million$81.47 millionViewListenView Earnings Details
10/31/2012Q312$0.10$0.38$75.20 million$77.44 millionViewN/AView Earnings Details
7/31/2012$0.27$0.27ViewN/AView Earnings Details
5/3/2012$0.27$0.36ViewN/AView Earnings Details
2/16/2012$0.24$0.40ViewN/AView Earnings Details
11/4/2011$0.82$0.47ViewN/AView Earnings Details
8/1/2011$0.10$0.01ViewN/AView Earnings Details
5/5/2011$0.17($0.02)ViewN/AView Earnings Details
2/17/2011$0.17$0.09ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Acorda Therapeutics (NASDAQ:ACOR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.03)($0.03)($0.03)
Q3 20171$0.21$0.21$0.21
Q4 20171$0.32$0.32$0.32
(Data provided by Zacks Investment Research)


Dividend History for Acorda Therapeutics (NASDAQ:ACOR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Acorda Therapeutics (NASDAQ:ACOR)
Insider Ownership Percentage: 8.00%
Insider Trades by Quarter for Acorda Therapeutics (NASDAQ:ACOR)
Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)
Insider Trades by Quarter for Acorda Therapeutics (NASDAQ:ACOR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Andrew A HindmanInsiderSell7,704$15.75$121,338.00View SEC Filing  
12/14/2016Ron CohenInsiderSell40,172$20.75$833,569.00View SEC Filing  
10/21/2016Richard P BatyckyInsiderSell2,063$20.30$41,878.90View SEC Filing  
10/7/2016David LawrenceInsiderSell250$20.82$5,205.00View SEC Filing  
10/3/2016Jane WasmanInsiderSell3,750$20.78$77,925.00View SEC Filing  
9/23/2016Jane WasmanInsiderSell500$27.32$13,660.00View SEC Filing  
6/22/2016David LawrenceInsiderSell500$25.09$12,545.00View SEC Filing  
6/8/2016Steven M RauscherDirectorSell1,086$27.83$30,223.38View SEC Filing  
5/13/2016Andrew A HindmanInsiderSell4,860$26.11$126,894.60View SEC Filing  
4/19/2016Lorin RandallDirectorSell1,488$28.68$42,675.84View SEC Filing  
1/4/2016Ian F. SmithDirectorSell13,231$41.85$553,717.35View SEC Filing  
12/23/2015Jane WasmaninsiderSell10,751$43.10$463,368.10View SEC Filing  
12/22/2015Lauren M. SabellainsiderSell7,113$42.04$299,030.52View SEC Filing  
12/21/2015Jane WasmanInsiderSell817$42.00$34,314.00View SEC Filing  
12/18/2015David LawrenceinsiderSell39,026$40.63$1,585,626.38View SEC Filing  
12/17/2015Lauren M. SabellainsiderSell14,229$40.00$569,160.00View SEC Filing  
12/1/2015Enrique J CarrazanaInsiderSell7,218$38.08$274,861.44View SEC Filing  
12/1/2015Ron CohenCEOSell11,850$38.08$451,248.00View SEC Filing  
10/19/2015Andrew BlightinsiderSell32,500$30.87$1,003,275.00View SEC Filing  
10/7/2015Michael W. RogersCFOSell5,700$30.24$172,368.00View SEC Filing  
10/5/2015Jane WasmaninsiderSell3,750$31.75$119,062.50View SEC Filing  
10/5/2015Ron CohenCEOSell135,000$28.03$3,784,050.00View SEC Filing  
9/21/2015Andrew BlightinsiderSell13,085$31.30$409,560.50View SEC Filing  
5/15/2015Andrew A HindmanInsiderSell4,779$29.82$142,509.78View SEC Filing  
1/12/2015Enrique J CarrazanaInsiderSell97,993$42.21$4,136,284.53View SEC Filing  
12/18/2014David LawrenceInsiderSell27,109$40.11$1,087,341.99View SEC Filing  
12/18/2014John P KelleyDirectorSell10,000$40.00$400,000.00View SEC Filing  
12/1/2014David LawrenceInsiderSell8,898$35.60$316,768.80View SEC Filing  
12/1/2014Lauren M SabellaVPSell3,242$35.58$115,350.36View SEC Filing  
12/1/2014Michael W RogersCFOSell230$35.58$8,183.40View SEC Filing  
12/1/2014Ron CohenCEOSell34,394$35.59$1,224,082.46View SEC Filing  
10/7/2014Michael W RogersCFOSell5,700$33.10$188,670.00View SEC Filing  
10/3/2014Jane WasmanInsiderSell3,750$34.13$127,987.50View SEC Filing  
9/24/2014Jane WasmanInsiderSell14,923$36.00$537,228.00View SEC Filing  
8/27/2014Jane WasmanInsiderSell14,923$33.00$492,459.00View SEC Filing  
12/5/2013Lauren SabellaVPSell8,797$31.81$279,832.57View SEC Filing  
12/2/2013Enrique CarrazanaInsiderSell1,640$33.56$55,038.40View SEC Filing  
10/15/2013Enrique J CarrazanaInsiderSell3,333$32.38$107,922.54View SEC Filing  
10/3/2013Jane WasmanInsiderSell3,750$35.74$134,025.00View SEC Filing  
8/20/2013Ron CohenCEOSell149,000$34.10$5,080,900.00View SEC Filing  
8/2/2013John KelleyDirectorSell15,000$38.00$570,000.00View SEC Filing  
7/19/2013Andrew BlightInsiderSell19,296$37.82$729,774.72View SEC Filing  
6/10/2013Ron CohenCEOSell11,000$34.15$375,650.00View SEC Filing  
5/8/2013Sandra Phd PanemDirectorSell10,000$33.80$338,000.00View SEC Filing  
12/4/2012Lauren M SabellaVPSell4,364$24.58$107,267.12View SEC Filing  
12/3/2012Andrew BlightInsiderSell7,200$24.20$174,240.00View SEC Filing  
12/3/2012David LawrenceCFOSell9,313$24.21$225,467.73View SEC Filing  
12/3/2012Ron CohenCEOSell16,407$24.22$397,377.54View SEC Filing  
11/13/2012Sandra Phd PanemDirectorSell22,569$24.12$544,364.28View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Acorda Therapeutics (NASDAQ:ACOR)
Latest Headlines for Acorda Therapeutics (NASDAQ:ACOR)
DateHeadline logoForm 8-K ACORDA THERAPEUTICS INC For: May 18 - - May 18 at 12:30 PM logoAcorda to Present New INBRIJA™ (Levodopa Inhalation Powder) Phase 3 Data at Upcoming MDS Congress - May 18 at 12:30 PM logoAndrew A. Hindman Sells 7,704 Shares of Acorda Therapeutics Inc (ACOR) Stock - May 17 at 4:26 PM logoAcorda Therapeutics Inc (ACOR) Receives Consensus Rating of "Buy" from Analysts - May 15 at 2:46 PM logo$139.89 Million in Sales Expected for Acorda Therapeutics Inc (ACOR) This Quarter - May 11 at 12:44 PM logo Analysts Expect Acorda Therapeutics Inc (ACOR) to Post $0.12 Earnings Per Share - May 9 at 9:44 AM logoAcorda to Present at the Deutsche Bank 42nd Annual Healthcare ... - Business Wire (press release) - May 2 at 3:23 PM logoAcorda to Present at the Deutsche Bank 42nd Annual Healthcare Conference - May 2 at 3:23 PM logoPositive News Coverage Likely to Impact Acorda Therapeutics (ACOR) Stock Price - May 2 at 7:52 AM logoAcorda Expands Alexa Skill Offering for Parkinson’s Awareness Month - April 30 at 1:31 AM logoAcorda (ACOR) Q1 Loss Wider Than Expected, Revenues Miss - April 28 at 3:32 PM logoSomewhat Positive News Coverage Likely to Impact Acorda Therapeutics (ACOR) Share Price - April 28 at 10:58 AM logoEdited Transcript of ACOR earnings conference call or presentation 27-Apr-17 12:30pm GMT - April 28 at 1:40 AM logoAcorda Shares Fall 5% in an Earnings Miss - April 28 at 1:40 AM logoBRIEF-Acorda qtrly GAAP net loss $0.41 per diluted share - April 27 at 8:39 PM logoAcorda Provides Financial and Pipeline Update for First Quarter 2017 - April 27 at 8:38 PM logoAcorda Therapeutics Inc (ACOR) Downgraded by TheStreet - April 27 at 4:16 PM logoAcorda Therapeutics Inc (ACOR) Announces Earnings Results - April 27 at 3:39 PM logoAcorda Therapeutics' (ACOR) CEO Ron Cohen on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha - April 27 at 3:38 PM logoCORRECTING and REPLACING Acorda Provides Financial and Pipeline Update for First Quarter 2017 - April 27 at 3:38 PM logoAcorda Puts 4 Drugs On Back Burner After Patent Setback - April 27 at 3:38 PM logoMaking Sense of Thursday's Flood of Biotech and Pharma Earnings Reports - April 27 at 3:38 PM logoAcorda Topples To 11-Year Low On Street-Lagging Q1 Sales, Losses - April 27 at 3:38 PM logoAcorda reports 1Q loss - April 27 at 6:44 AM logoSomewhat Favorable News Coverage Likely to Affect Acorda Therapeutics (ACOR) Stock Price - April 24 at 11:47 AM logoAcorda Therapeutics (ACOR) Given Daily Coverage Optimism Score of 0.07 - April 21 at 8:17 AM logoZacks: Brokerages Anticipate Acorda Therapeutics Inc (ACOR) Will Announce Quarterly Sales of $125.93 Million - April 20 at 2:48 PM logoAcorda Therapeutics Inc (ACOR) Given Average Recommendation of "Buy" by Brokerages - April 18 at 5:04 PM logoAcorda Therapeutics Inc (ACOR) Expected to Post Earnings of -$0.16 Per Share - April 18 at 9:08 AM logoAcorda Therapeutics (ACOR) Getting Positive News Coverage, Report Finds - April 17 at 10:07 AM logoAcorda Therapeutics (ACOR) Getting Somewhat Positive Media Coverage, AlphaOne Reports - April 14 at 1:52 PM logoAcorda to Host Conference Call to Discuss First Quarter 2017 on April 27, 2017 - Yahoo Finance - April 13 at 3:33 PM logoAcorda to Host Conference Call to Discuss First Quarter 2017 on April 27, 2017 - April 13 at 3:33 PM logoACORDA NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics Inc. To Contact The Firm - April 8 at 11:26 AM logoForm 8-K ACORDA THERAPEUTICS INC For: Apr 03 - April 7 at 3:18 PM logoAcorda restructures, cuts headcount 20% - Seeking Alpha - April 7 at 6:01 AM logoForm 8-K ACORDA THERAPEUTICS INC For: Apr 03 - - April 7 at 6:01 AM logoAcorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs - April 7 at 6:01 AM logoAcorda Therapeutics to cut 20 pct of workforce - April 7 at 6:01 AM logoAcorda CEO Risks All, Loses Nothing, When Drug Patent Strategy Backfires, Employees Fired - April 7 at 6:01 AM logoAcorda (ACOR) to Reduce Workforce, Focus on Product Pipeline - April 7 at 6:01 AM logoAcorda Trims 20% Of Workforce, But Looming Cuts Could Be Deeper - April 7 at 6:01 AM logoStifel Nicolaus Reiterates "Buy" Rating for Acorda Therapeutics Inc (ACOR) - April 5 at 2:31 PM logoAcorda Therapeutics Inc Expected to Post Q2 2017 Earnings of ($0.03) Per Share (ACOR) - April 5 at 12:28 PM logoAcorda Therapeutics Inc (ACOR) Short Interest Update - April 4 at 1:04 PM logoAcorda Therapeutics Inc. (ACOR) Plunged After Ampyra Patents Invalidated - April 3 at 8:28 PM logoWhy Acorda Therapeutics Inc Plummeted for a Second Straight Day - April 3 at 8:28 PM logoJPMorgan Downgrades Acorda Therapeutics, Inc. (ACOR) to Neutral - - April 3 at 3:28 PM logoAcorda's (ACOR) MS Drug Patents Invalidated, Shares Plunge - April 3 at 3:28 PM logoAcorda Therapeutics Inc (ACOR) Stock Rating Reaffirmed by Cowen and Company - April 3 at 1:17 PM



Acorda Therapeutics (ACOR) Chart for Tuesday, May, 30, 2017

This page was last updated on 5/30/2017 by Staff